Author Archive: AZBio

Important Update on FinCEN Beneficial Ownership Information Reporting Requirements

Posted on by

“With the February 18, 2025, decision by the U.S. District Court for the Eastern District of Texas in Smith, et al. v. U.S. Department of the Treasury, et al., 6:24-cv-00336 (E.D. Tex.), beneficial ownership information (BOI) reporting requirements under the Corporate
Transparency Act (CTA) are once again back in effect.”

According to FIN-2025-CTA1 (2/18/2025), for the vast majority of reporting companies, the new deadline to file an initial, updated, and/or corrected BOI report is now March 21, 2025. FinCEN will provide an update before then of any further modification of this deadline, recognizing that reporting companies may need additional time to comply with their BOI reporting obligations once this update is provided.

Companies that have not yet completed the FinCEN BOI process can access the full alert below.  Contact your legal advisers for further information. 

https://www.fincen.gov/sites/default/files/shared/FinCEN-BOI-Notice-Deadline-Extension-508FINAL.pdf

HonorHealth Innovations (H2I) is joining Investor Corner PBC

Posted on by

PHOENIX, AZ – February 20, 2025 – Phoenix Bioscience Core (PBC) is pleased to announce that HonorHealth Innovations (H2I) is joining Investor Corner PBC, further strengthening the region’s ecosystem for healthcare innovation and investment. Investor Corner PBC is purposely situated within Connect Labs by Wexford, a flexible, scale-in-place lab and innovation hub located at Wexford Science & Technology’s 850 PBC facility and a cornerstone of Greater Phoenix’s thriving startup ecosystem.Continue reading→

A Bill at the Arizona Legislature Would Give Arizona Another Tool to Drive Growth in our Life Science Sector

Posted on by

Senate Bill 1539 expands the clean room transaction privilege tax (TPT) deduction and use tax exemption to include any clean room used for manufacturing, processing, fabrication or research and development, rather than only clean rooms used for manufacturing, processing, fabrication or research and development of semiconductor products. The bill received a “do pass” recommendation in the Senate Finance Committee on February 17, 2025.Continue reading→

NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial

Posted on by

Tucson, AZ, February 14, 2025 –(PR.com)– NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will enable the company to commence the Phase IIb NOVEL trial (NanO2 in Large VessEL Occlusion Stroke (NOVEL): a multicentre single-blind, randomised, placebo-controlled blinded biomarker end-point clinical trial of perfluorocarbon in acute ischaemic stroke due to large vessel occlusion (LVO).Continue reading→

The Stephenson Global Pancreatic Cancer Research Institute Launches First-of-Its-Kind Global Scientific Awards to Advance Breakthrough Discovery in Pancreatic Cancer

Posted on by
  • Stephenson Global Prize opportunity invites top scientific minds for one of the largest privately funded rewards — Call for Nominations open now through March 14.
  • Stephenson Global Scholar Grants seek the most innovative solutions to tackle the challenges of pancreatic cancer — Grant Applications open now through March 14.

Continue reading→